Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 329

1.

Methods of measurement for tumor mutational burden in tumor tissue.

Meléndez B, Van Campenhout C, Rorive S, Remmelink M, Salmon I, D'Haene N.

Transl Lung Cancer Res. 2018 Dec;7(6):661-667. doi: 10.21037/tlcr.2018.08.02. Review.

2.

The Prognostic Value of the Combination of Low VEGFR-1 and High VEGFR-2 Expression in Endothelial Cells of Colorectal Cancer.

D'Haene N, Koopmansch C, Van Eycke YR, Hulet F, Allard J, Bouri S, Rorive S, Remmelink M, Decaestecker C, Maris C, Salmon I.

Int J Mol Sci. 2018 Nov 9;19(11). pii: E3536. doi: 10.3390/ijms19113536.

3.

SMAD4 Mutation in Small Cell Transformation of Epidermal Growth Factor Receptor Mutated Lung Adenocarcinoma.

D'Haene N, Le Mercier M, Salmon I, Mekinda Z, Remmelink M, Berghmans T.

Oncologist. 2018 Nov 9. pii: theoncologist.2018-0016. doi: 10.1634/theoncologist.2018-0016. [Epub ahead of print]

PMID:
30413663
4.

Comparing the expression profiles of steroid hormone receptors and stromal cell markers in prostate cancer at different Gleason scores.

Gevaert T, Van Eycke YR, Vanden Broeck T, Van Poppel H, Salmon I, Rorive S, Claessens F, De Ridder D, Decaestecker C, Joniau S.

Sci Rep. 2018 Sep 25;8(1):14326. doi: 10.1038/s41598-018-32711-9.

5.

UCA1 overexpression is associated with less aggressive subtypes of bladder cancer.

Lebrun L, Milowich D, Le Mercier M, Allard J, Van Eycke YR, Roumeguere T, Decaestecker C, Salmon I, Rorive S.

Oncol Rep. 2018 Nov;40(5):2497-2506. doi: 10.3892/or.2018.6697. Epub 2018 Sep 10.

6.

Segmentation of glandular epithelium in colorectal tumours to automatically compartmentalise IHC biomarker quantification: A deep learning approach.

Van Eycke YR, Balsat C, Verset L, Debeir O, Salmon I, Decaestecker C.

Med Image Anal. 2018 Oct;49:35-45. doi: 10.1016/j.media.2018.07.004. Epub 2018 Jul 12.

PMID:
30081241
7.

Molecular Study of Long-Term Survivors of Glioblastoma by Gene-Targeted Next-Generation Sequencing.

Cantero D, Rodríguez de Lope Á, Moreno de la Presa R, Sepúlveda JM, Borrás JM, Castresana JS, D'Haene N, García JF, Salmon I, Mollejo M, Rey JA, Hernández-Laín A, Meléndez B.

J Neuropathol Exp Neurol. 2018 Aug 1;77(8):710-716. doi: 10.1093/jnen/nly048.

PMID:
30010995
8.

YAP and TAZ are essential for basal and squamous cell carcinoma initiation.

Debaugnies M, Sánchez-Danés A, Rorive S, Raphaël M, Liagre M, Parent MA, Brisebarre A, Salmon I, Blanpain C.

EMBO Rep. 2018 Jul;19(7). pii: e45809. doi: 10.15252/embr.201845809. Epub 2018 Jun 6.

PMID:
29875149
9.

Clinical application of targeted next-generation sequencing for colorectal cancer patients: a multicentric Belgian experience.

D'Haene N, Fontanges Q, De Nève N, Blanchard O, Melendez B, Delos M, Dehou MF, Maris C, Nagy N, Rousseau E, Vandenhove J, Gilles A, De Prez C, Verset L, Van Craynest MP, Demetter P, Van Laethem JL, Salmon I, Le Mercier M.

Oncotarget. 2018 Apr 17;9(29):20761-20768. doi: 10.18632/oncotarget.25099. eCollection 2018 Apr 17.

10.

Identification of the tumour transition states occurring during EMT.

Pastushenko I, Brisebarre A, Sifrim A, Fioramonti M, Revenco T, Boumahdi S, Van Keymeulen A, Brown D, Moers V, Lemaire S, De Clercq S, Minguijón E, Balsat C, Sokolow Y, Dubois C, De Cock F, Scozzaro S, Sopena F, Lanas A, D'Haene N, Salmon I, Marine JC, Voet T, Sotiropoulou PA, Blanpain C.

Nature. 2018 Apr;556(7702):463-468. doi: 10.1038/s41586-018-0040-3. Epub 2018 Apr 18.

PMID:
29670281
11.

Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial.

Tosco L, Laenen A, Gevaert T, Salmon I, Decaestecker C, Davicioni E, Buerki C, Claessens F, Swinnen J, Goffin K, Oyen R, Everaerts W, Moris L, De Meerleer G, Haustermans K, Joniau S; P.E.A.R.L. (ProstatE cAncer Research Leuven).

BMC Cancer. 2018 Apr 2;18(1):354. doi: 10.1186/s12885-018-4275-z.

12.

Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma.

Duerinck J, Du Four S, Bouttens F, Andre C, Verschaeve V, Van Fraeyenhove F, Chaskis C, D'Haene N, Le Mercier M, Rogiers A, Michotte A, Salmon I, Neyns B.

J Neurooncol. 2018 Jan;136(1):115-125. doi: 10.1007/s11060-017-2629-z. Epub 2017 Oct 7.

PMID:
28988341
13.

Toward a new and noninvasive diagnostic method of papillary thyroid cancer by using peptide vectorized contrast agents targeted to galectin-1.

Fanfone D, Despretz N, Stanicki D, Rubio-Magnieto J, Fossépré M, Surin M, Rorive S, Salmon I, Vander Elst L, Laurent S, Muller RN, Saussez S, Burtea C.

Med Oncol. 2017 Oct 6;34(11):184. doi: 10.1007/s12032-017-1042-y.

PMID:
28986753
14.

CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib.

Raspé E, Coulonval K, Pita JM, Paternot S, Rothé F, Twyffels L, Brohée S, Craciun L, Larsimont D, Kruys V, Sandras F, Salmon I, Van Laere S, Piccart M, Ignatiadis M, Sotiriou C, Roger PP.

EMBO Mol Med. 2017 Aug;9(8):1052-1066. doi: 10.15252/emmm.201607084.

15.

ADAM-17/FHL2 colocalisation suggests interaction and role of these proteins in colorectal cancer.

Verset L, Tommelein J, Decaestecker C, De Vlieghere E, Bracke M, Salmon I, De Wever O, Demetter P.

Tumour Biol. 2017 Mar;39(3):1010428317695024. doi: 10.1177/1010428317695024.

PMID:
28349819
16.

Image processing in digital pathology: an opportunity to solve inter-batch variability of immunohistochemical staining.

Van Eycke YR, Allard J, Salmon I, Debeir O, Decaestecker C.

Sci Rep. 2017 Feb 21;7:42964. doi: 10.1038/srep42964.

17.

Clinical Application of Targeted Next Generation Sequencing for Colorectal Cancers.

Fontanges Q, De Mendonca R, Salmon I, Le Mercier M, D'Haene N.

Int J Mol Sci. 2016 Dec 16;17(12). pii: E2117. doi: 10.3390/ijms17122117. Review.

18.

Screening for peptides targeted to IL-7Rα for molecular imaging of rheumatoid arthritis synovium.

Burtea C, Laurent S, Sanli T, Fanfone D, Devalckeneer A, Sauvage S, Beckers MC, Rorive S, Salmon I, Vander Elst L, Lauwerys BR, Muller RN.

Arthritis Res Ther. 2016 Oct 12;18(1):230.

19.

A 63-Year-Old Woman with a Right Frontal Lesion.

Koopmansch C, D'Haene N, Hastir D, Sadeghi N, Maris C, Salmon I.

Brain Pathol. 2016 Jul;26(4):555-6. doi: 10.1111/bpa.12393. No abstract available.

PMID:
27322935
20.

Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma.

Duerinck J, Du Four S, Vandervorst F, D'Haene N, Le Mercier M, Michotte A, Van Binst AM, Everaert H, Salmon I, Bouttens F, Verschaeve V, Neyns B.

J Neurooncol. 2016 May;128(1):147-155. doi: 10.1007/s11060-016-2092-2. Epub 2016 Mar 2.

PMID:
26935577
21.

High-throughput analysis of tissue-based biomarkers in digital pathology.

Van Eycke YR, Debeir O, Verset L, Demetter P, Salmon I, Decaestecker C.

Conf Proc IEEE Eng Med Biol Soc. 2015;2015:7732-5. doi: 10.1109/EMBC.2015.7320184.

PMID:
26738084
22.

[Next generation sequencing].

Le Mercier M, D'Haene N, Rorive S, Degand C, De Nève N, Blanchard O, Salmon I.

Rev Med Brux. 2016;37(5):436-438. French.

PMID:
28525213
23.

[How molecular biology can improve the clinical diagnosis of gliomas?]

D'Haene N, Blanchard O, De Nève N, Evens J, Maris C, Rorive S, Le Mercier M, Salmon I.

Rev Med Brux. 2016;37(3):152-158. Review. French.

PMID:
28525188
24.

Clinical Validation of Targeted Next Generation Sequencing for Colon and Lung Cancers.

D'Haene N, Le Mercier M, De Nève N, Blanchard O, Delaunoy M, El Housni H, Dessars B, Heimann P, Remmelink M, Demetter P, Tejpar S, Salmon I.

PLoS One. 2015 Sep 14;10(9):e0138245. doi: 10.1371/journal.pone.0138245. eCollection 2015.

25.

IGF-IR: a new prognostic biomarker for human glioblastoma.

Maris C, D'Haene N, Trépant AL, Le Mercier M, Sauvage S, Allard J, Rorive S, Demetter P, Decaestecker C, Salmon I.

Br J Cancer. 2015 Sep 1;113(5):729-37. doi: 10.1038/bjc.2015.242. Epub 2015 Aug 20.

26.

Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity.

Van Keymeulen A, Lee MY, Ousset M, Brohée S, Rorive S, Giraddi RR, Wuidart A, Bouvencourt G, Dubois C, Salmon I, Sotiriou C, Phillips WA, Blanpain C.

Nature. 2015 Sep 3;525(7567):119-23. doi: 10.1038/nature14665. Epub 2015 Aug 12.

PMID:
26266985
27.

Diagnostic value of the UCA1 test for bladder cancer detection: a clinical study.

Milowich D, Le Mercier M, De Neve N, Sandras F, Roumeguere T, Decaestecker C, Salmon I, Rorive S.

Springerplus. 2015 Jul 16;4:349. doi: 10.1186/s40064-015-1092-6. eCollection 2015.

28.

Microsatellite instable vs stable colon carcinomas: analysis of tumour heterogeneity, inflammation and angiogenesis.

De Smedt L, Lemahieu J, Palmans S, Govaere O, Tousseyn T, Van Cutsem E, Prenen H, Tejpar S, Spaepen M, Matthijs G, Decaestecker C, Moles Lopez X, Demetter P, Salmon I, Sagaert X.

Br J Cancer. 2015 Jul 28;113(3):500-9. doi: 10.1038/bjc.2015.213. Epub 2015 Jun 11.

29.

Impact of neoadjuvant therapy on cancer-associated fibroblasts in rectal cancer.

Verset L, Tommelein J, Moles Lopez X, Decaestecker C, Boterberg T, De Vlieghere E, Salmon I, Mareel M, Bracke M, De Wever O, Demetter P.

Radiother Oncol. 2015 Sep;116(3):449-54. doi: 10.1016/j.radonc.2015.05.007. Epub 2015 May 25.

PMID:
26021554
30.

Morphometric and quantitative immunohistochemical analysis of disease-related changes in the upper (suburothelial) lamina propria of the human bladder dome.

Gevaert T, Moles Lopez X, Sagaert X, Libbrecht L, Roskams T, Rorive S, Decaestecker C, Salmon I, De Ridder D.

PLoS One. 2015 May 14;10(5):e0127020. doi: 10.1371/journal.pone.0127020. eCollection 2015.

31.

Development of a peptide-functionalized imaging nanoprobe for the targeting of (FXYD2)γa as a highly specific biomarker of pancreatic beta cells.

Burtea C, Laurent S, Crombez D, Delcambre S, Sermeus C, Millard I, Rorive S, Flamez D, Beckers MC, Salmon I, Vander Elst L, Eizirik DL, Muller RN.

Contrast Media Mol Imaging. 2015 Sep-Oct;10(5):398-412. doi: 10.1002/cmmi.1641. Epub 2015 Apr 30.

PMID:
25930968
32.

Different levels of Twist1 regulate skin tumor initiation, stemness, and progression.

Beck B, Lapouge G, Rorive S, Drogat B, Desaedelaere K, Delafaille S, Dubois C, Salmon I, Willekens K, Marine JC, Blanpain C.

Cell Stem Cell. 2015 Jan 8;16(1):67-79. doi: 10.1016/j.stem.2014.12.002.

33.

Sonic hedgehog and Gli1 expression predict outcome in resected pancreatic adenocarcinoma.

Maréchal R, Bachet JB, Calomme A, Demetter P, Delpero JR, Svrcek M, Cros J, Bardier-Dupas A, Puleo F, Monges G, Hammel P, Louvet C, Paye F, Bachelier P, Le Treut YP, Vaillant JC, Sauvanet A, André T, Salmon I, Devière J, Emile JF, Van Laethem JL.

Clin Cancer Res. 2015 Mar 1;21(5):1215-24. doi: 10.1158/1078-0432.CCR-14-0667. Epub 2014 Dec 31.

34.

Identification of OLIG2 as the most specific glioblastoma stem cell marker starting from comparative analysis of data from similar DNA chip microarray platforms.

Trépant AL, Bouchart C, Rorive S, Sauvage S, Decaestecker C, Demetter P, Salmon I.

Tumour Biol. 2015 Mar;36(3):1943-53. doi: 10.1007/s13277-014-2800-5. Epub 2014 Nov 12.

PMID:
25384509
35.

Immunohistochemical toolkit for tracking and quantifying xenotransplanted human stem cells.

Allard J, Li K, Lopez XM, Blanchard S, Barbot P, Rorive S, Decaestecker C, Pochet R, Bohl D, Lepore AC, Salmon I, Nicaise C.

Regen Med. 2014;9(4):437-52. doi: 10.2217/rme.14.26.

36.

Registration of whole immunohistochemical slide images: an efficient way to characterize biomarker colocalization.

Moles Lopez X, Barbot P, Van Eycke YR, Verset L, Trépant AL, Larbanoix L, Salmon I, Decaestecker C.

J Am Med Inform Assoc. 2015 Jan;22(1):86-99. doi: 10.1136/amiajnl-2014-002710. Epub 2014 Aug 14.

37.

SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma.

Boumahdi S, Driessens G, Lapouge G, Rorive S, Nassar D, Le Mercier M, Delatte B, Caauwe A, Lenglez S, Nkusi E, Brohée S, Salmon I, Dubois C, del Marmol V, Fuks F, Beck B, Blanpain C.

Nature. 2014 Jul 10;511(7508):246-50. doi: 10.1038/nature13305. Epub 2014 Jun 8.

PMID:
24909994
38.

Galectins and neovascularization in central nervous system tumors.

D'Haene N, Maris C, Rorive S, Decaestecker C, Le Mercier M, Salmon I.

Glycobiology. 2014 Oct;24(10):892-8. doi: 10.1093/glycob/cwu049. Epub 2014 May 26. Review.

PMID:
24861052
39.

Next-generation sequencing improves the diagnosis of thyroid FNA specimens with indeterminate cytology.

Le Mercier M, D'Haene N, De Nève N, Blanchard O, Degand C, Rorive S, Salmon I.

Histopathology. 2015 Jan;66(2):215-24. doi: 10.1111/his.12461. Epub 2014 Nov 10.

PMID:
24834793
40.

An automated blur detection method for histological whole slide imaging.

Moles Lopez X, D'Andrea E, Barbot P, Bridoux AS, Rorive S, Salmon I, Debeir O, Decaestecker C.

PLoS One. 2013 Dec 13;8(12):e82710. doi: 10.1371/journal.pone.0082710. eCollection 2013.

41.

VEGFR1 and VEGFR2 involvement in extracellular galectin-1- and galectin-3-induced angiogenesis.

D'Haene N, Sauvage S, Maris C, Adanja I, Le Mercier M, Decaestecker C, Baum L, Salmon I.

PLoS One. 2013 Jun 17;8(6):e67029. doi: 10.1371/journal.pone.0067029. Print 2013.

42.

Epithelial expression of FHL2 is negatively associated with metastasis-free and overall survival in colorectal cancer.

Verset L, Tommelein J, Moles Lopez X, Decaestecker C, Mareel M, Bracke M, Salmon I, De Wever O, Demetter P.

Br J Cancer. 2013 Jul 9;109(1):114-20. doi: 10.1038/bjc.2013.290. Epub 2013 Jun 11.

43.

S100A2 is a predictive biomarker of adjuvant therapy benefit in pancreatic adenocarcinoma.

Bachet JB, Maréchal R, Demetter P, Bonnetain F, Cros J, Svrcek M, Bardier-Dupas A, Hammel P, Sauvanet A, Louvet C, Paye F, Vaillant JC, André T, Closset J, Salmon I, Emile JF, Van Laethem JL.

Eur J Cancer. 2013 Aug;49(12):2643-53. doi: 10.1016/j.ejca.2013.04.017. Epub 2013 May 28.

PMID:
23726265
44.
45.

Single-center experience with ipilimumab in an expanded access program for patients with pretreated advanced melanoma.

Wilgenhof S, Du Four S, Vandenbroucke F, Everaert H, Salmon I, Liénard D, Marmol VD, Neyns B.

J Immunother. 2013 Apr;36(3):215-22. doi: 10.1097/CJI.0b013e31828eed39.

PMID:
23502769
46.

Adult interfollicular tumour-initiating cells are reprogrammed into an embryonic hair follicle progenitor-like fate during basal cell carcinoma initiation.

Youssef KK, Lapouge G, Bouvrée K, Rorive S, Brohée S, Appelstein O, Larsimont JC, Sukumaran V, Van de Sande B, Pucci D, Dekoninck S, Berthe JV, Aerts S, Salmon I, del Marmol V, Blanpain C.

Nat Cell Biol. 2012 Dec;14(12):1282-94. doi: 10.1038/ncb2628. Epub 2012 Nov 25.

PMID:
23178882
47.

A simplified approach for the molecular classification of glioblastomas.

Le Mercier M, Hastir D, Moles Lopez X, De Nève N, Maris C, Trepant AL, Rorive S, Decaestecker C, Salmon I.

PLoS One. 2012;7(9):e45475. doi: 10.1371/journal.pone.0045475. Epub 2012 Sep 18.

48.

Molecular changes in pancreatic cancer: implications for molecular targeting therapy.

Demetter P, Maréchal R, Verset L, Salmon I, Bachet JB, Van Laethem JL.

Acta Gastroenterol Belg. 2012 Jun;75(2):210-4. Review.

PMID:
22870784
49.

Clustering methods applied in the detection of Ki67 hot-spots in whole tumor slide images: an efficient way to characterize heterogeneous tissue-based biomarkers.

Lopez XM, Debeir O, Maris C, Rorive S, Roland I, Saerens M, Salmon I, Decaestecker C.

Cytometry A. 2012 Sep;81(9):765-75. doi: 10.1002/cyto.a.22085. Epub 2012 Jun 22.

50.

Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma.

Maréchal R, Bachet JB, Mackey JR, Dalban C, Demetter P, Graham K, Couvelard A, Svrcek M, Bardier-Dupas A, Hammel P, Sauvanet A, Louvet C, Paye F, Rougier P, Penna C, André T, Dumontet C, Cass CE, Jordheim LP, Matera EL, Closset J, Salmon I, Devière J, Emile JF, Van Laethem JL.

Gastroenterology. 2012 Sep;143(3):664-674.e6. doi: 10.1053/j.gastro.2012.06.006. Epub 2012 Jun 13.

PMID:
22705007

Supplemental Content

Loading ...
Support Center